{
    "clinical_study": {
        "@rank": "111096", 
        "arm_group": [
            {
                "arm_group_label": "Tolvaptan first, then Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tolvaptan twice daily in first intervention period and placebo twice daily in second intervention period. (after washout period)"
            }, 
            {
                "arm_group_label": "Placebo first, then Tolvaptan", 
                "arm_group_type": "Experimental", 
                "description": "Placebo twice daily in first intervention period and Tolvaptan twice daily in second intervention period. (after washout period)"
            }
        ], 
        "brief_summary": {
            "textblock": "In this study the investigators propose to use a daily dose of 45 mg (30 mg at 8 AM and 15\n      mg at 4 PM). This relatively small well-tolerated dose is likely to persistently increase\n      urine volume and reduce urine supersaturation and to be well tolerated by patients with\n      kidney stone disease and normal renal function (see below). The twice-daily (8 AM and 4 PM)\n      regimen is designed to produce a maximal AVP inhibition on waking with a gradual fall-off of\n      effect during the night. To this end, a higher dose is used in the morning, with a lower\n      dose in the afternoon."
        }, 
        "brief_title": "Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Nephrolithiasis, Calcium Oxalate", 
            "Nephrolithiasis, Calcium Phosphate"
        ], 
        "condition_browse": {
            "mesh_term": "Nephrolithiasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of calcium oxalate or calcium phosphate stone.\n\n          -  Good renal function\n\n        Exclusion Criteria:\n\n          -  History of hypo-or hypernatremia.\n\n          -  History of hypotension or orthostatic dizziness.\n\n          -  Clinical history of congestive heart failure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096965", 
            "org_study_id": "11-001780"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Tolvaptan first, then Placebo", 
                    "Placebo first, then Tolvaptan"
                ], 
                "description": "Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).", 
                "intervention_name": "Tolvaptan", 
                "intervention_type": "Drug", 
                "other_name": "Samsca"
            }, 
            {
                "arm_group_label": [
                    "Tolvaptan first, then Placebo", 
                    "Placebo first, then Tolvaptan"
                ], 
                "description": "Patients will receive daily dose at 8 AM and at 4 PM.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Calcium oxalate", 
            "Calcium phosphate", 
            "Kidney stone"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "contact": {
                "email": "kraft.ruth@mayo.edu", 
                "last_name": "Ruth A. Kraft, Research Coordinator", 
                "phone": "507-266-8133"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "investigator": {
                "last_name": "Dr. John Lieske, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study", 
        "overall_contact": {
            "email": "kraft.ruth@mayo.edu", 
            "last_name": "Ruth A. Kraft", 
            "phone": "507-266-8133"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "John Lieske, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Calcium oxalate (CaOx) SS is primary endpoint for CaOx stone formers.", 
                "measure": "Change in urinary calcium oxalate supersaturation (SS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 3 weeks"
            }, 
            {
                "description": "Calcium phosphate (CaPhos) SS is the primary endpoint for CaPhos stone formers.", 
                "measure": "Change in Calcium phosphate SS", 
                "safety_issue": "No", 
                "time_frame": "Baseline to three weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096965"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "John Lieske", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}